Rhenium-186 HEDP: Palliative radionuclide therapy of painful bone metastases

Scandinavian Journal of Urology and Nephrology

Volumn 31, Issue 5, 1997, Pages 445-448

  Schoeneich, G ^a,b   Palmedo, H ^a   Dierke Dzierzon, C ^a   Muller S C ^a   Biersack, H J ^a  

^a UNIVERSITY OF BONN   (Germany)

^b Klinik und Poliklinik für Mund Kiefer und Gesichtschirurgie   (Germany)

Author keywords

Disseminated bone metastases; Pain relief; Prostate and breast cancer; Quality of life; Radionuclide therapy; Rhenium 186 HEDP

Indexed keywords

ETIDRONIC ACID TC 99M; RHENIUM 186;

ARTICLE; BONE METASTASIS; CANCER PAIN; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CLINICAL ARTICLE; HUMAN; PRIORITY JOURNAL; QUALITY OF LIFE;

EID: 0030815360     PISSN: 00365599     EISSN: None     Source Type: Journal    
DOI: 10.3109/00365599709030639     Document Type: Article

References (27)

1. Blake GM, Zivanovic MA, McEvan AJ, Ackery DM. Sr-89 therapy: strontium kinetics in disseminated carcinoma of the proste. Eur J Nucl Med 1986; 12: 447-454.
2. Buchali K, Correns HJ, Schuerer M, Schnorr D, Lips H, Sydow K. Results of a double blind study of strontium-89 therapy of skeletal metastases of prostatic carcinoma. Eur J Nucl Med 1988; 14: 349-351.
3. De Klerk JMH, van Dijk A, van het Schip AD, Zonnenberg BA, van Rijk PP. Pharnacokinetics of rhenium-186 after administration of rhenium-186-HEDP to patients with bone metastases. J Nucl Med 1992; 33: 646-651.
4. De Klerk JMH, Zonnenberg BA, van het Schip AD, et al. Dose escalation study of rhenium-186 hydroxyethylidene diphophonate in patients with metastatic prostate cancer. Eur J Nucl Med 1994; 21: 1114-1120.
5. De Klerk JMH, van het Schip AD, Zonneberg BA. Evaluation of thrombocytopenia in patients treated with rhenium-186 HEDP: guidlines for individual dosage recommendation. J Nucl Med 1994; 35: 1423-1428.
6. Epstein LM, Stewart BH, Antunez AR. Half and total radiation for carcinoma of the prostate. J Urol 1979; 122: 330-333.
7. Eisenhut M. Preparation of Re-186 perrhenate for nuclear medical purpus. Int J Appl Radiat Isot 1982; 33: 99-103.
8. Firusian N, Mellin P, Schmidt CG. Results of strontium-89 therapy in patients with carcinoma to the prostate and incurable pain from bone metastases: a preliminary report. J Urol 1976; 116: 764-768.
9. Haesner M, Buchali K, Pink V, Lips H. Die Wirksamkeit der Therapie mit 89Sr-Strontiumchlorid bei 200 Patienten mit Skelettmetastasen eines Prostatakarzinoms. Nuklearmedizin; 1002; 31: 48-52.
10. Keen CW. Half body radiotherapy in the management of metastatic adenocarcinoma of the prostate. J Urol 1980; 123: 713-715.
11. Kuban DA, Delbridge T, El-Mahdi M. Half body irradiation for treatment of widely metastatic adenocarcinoma of the prostate. J Urol 1989; 141: 572-575.
12. Laing AH, Ackery DM, Bayly RJ, et al. Strontium-89 cloride for pain palliation in prostate skeletal malignancy. Br J Urol 1991; 64: 816-822.
13. Maxon HR, Schroder LE, Hertzzberg VS. Rhenium 186-HEDP for treatment of painful osseous metastases: results of a double blind cross over comparison with placebo. J Nucl Med 1991; 32: 1877-1881.
14. Maxon HR, Thomas SR, Hertzberg VS. Rhenium-186 HEDP for the treatment of painful osseous metastases. Semin Nucl Med 1992; 22: 33-40.
15. McEvan AJ, Porter AT, Venner PM, Amyotte G. An evaluation of the safety and efficacy of the treatment with strontium-89 in patients who have previously received wide field radiotherapy. Antibod Immunoconj Radiopharmacol 1990; 3: 91-98.
16. McEwan AJ, Amyotte GA, McGowan DG, MacGillivary JA, Porter AT. A retrospective analysis of the cost effectiveness of treatment with Metastron in patients with prostate cancer metastatic to bone. Eur Urol (Suppl) 1994; 26: 26-31.
17. Müller St, Rembrink K, Reiners Chr. Die nuklearmedizinische Schmerztherapie beim ossär metastasierten Prostatakarzinom. Urol Ausg A 1993; 32: 121-127.
18. Porter AT, McEvan AJ, Powe JE, et al. Results of a randomized phase-III trial to evaluate the efficancy of strontium-89 adjuvant to local field external beam irradiation in the management of endrocrine resiteant metastatic prostate cancer. Int J Radiat Oncol Biol Phys 1993; 25: 805-813.
19. Porter AT. Strontium-89 (Metastron) in the treatment of prostate cancer metastatic to bone. Eur Urol (Suppl) 1994; 26: 20-25.
20. Robinson RG, Spicer JA, Preston DF, Wegst AV, Martin NL. Treatment of metastati bone pain with strontium-89. Int J Radiat Appl Instrum B 1987; 14: 219-222.
21. Robinson RG, Blake GM, Preston DF, et al. Strontium-89: treatment results and kinetics in patients with painful metastatic prostate and breast cancer. Radiographics 1989; 9: 271-281.
22. Robinson RG, Preston DF, Spicer JA, Baxter KG. Radionuclide therapy of intractable bone pain: emphasis on strontium-89. Semin Nucl Med 1992; 22: 28-32.
23. Robinson RG, Preston DF, Schiefelbein M, Baxten KG. Strontium 89 therapy for palliation of pain due to osseous metastases. JAMA 1995; 274: 429-434.
24. Rowland CG, Bullimore JA, Smith PJB. Half body irradiation in the treatment of metastatic prostatic carcinoma. Br J Urol 1981; 53: 628-631.
25. Salzar OM, Rubin P, Hendrickson FR. Single bone half-body irradiation for palliation of multiple bone metastases from solid tumors: final Radiation Oncology Group report. Cancer 1986; 58: 29-36.
26. Tong D, Gillick L, Hendrikson FR. The palliation of symptomatic osseous metastases: final results of the study by the radiation Therapy Oncology Group. Cancer 1982; 30: 893-899.
27. Zonnenberg BA, De Klerk HJM, van Rijk PP. Re-186 HEDP for treatment of painful bone metastases in patients with inetastatic prostate or breast cancer. J Nucl Med 1991; 32: 1082-1091.